Clinical Trials
55 trialsMK-3475-G21
Merck Sharp & Dohme LLC
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Presage Biosciences
MK-3475-051
Merck Sharp & Dohme LLC
DS-3201b in Participants With Lymphomas
Daiichi Sankyo
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
ON-5001
OncoNano Medicine, Inc.
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Treeline Biosciences, Inc.
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
Incyte Corporation
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
QUANTUM
VitaMed Research LLC
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
Kyowa Kirin Co., Ltd.
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101
Eisai Inc.
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
TopAlliance Biosciences
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Fate Therapeutics
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin.
Genmab
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin.
Genmab
A Study of PNT2258 in Patients With Advanced Solid Tumors
Sierra Oncology LLC - a GSK company
PIVOT IO 020
Bristol-Myers Squibb
GEN602
Genzada Pharmaceuticals USA, Inc.
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Repertoire Immune Medicines
CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia
Presage Biosciences
SOLAR
miRagen Therapeutics, Inc.
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
Incyte Corporation
CTCL
Galderma R&D
PRISM
miRagen Therapeutics, Inc.
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Seagen Inc.
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Acrotech Biopharma Inc.
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Shenzhen BinDeBio Ltd.
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Solid Tumor Malignancies or Refractory Lymphoma
Celgene
Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies
Celgene
NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma
Celgene
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma
Janssen Research & Development, LLC
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
Mirna Therapeutics, Inc.
SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma
Progen Pharmaceuticals
BAY1238097, First in Man
Bayer
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
Astellas Pharma Inc
PXD101-CLN-6
Valerio Therapeutics
PCYC-0403
Pharmacyclics LLC.